

Ianalumab

| | |
|------------------|---|
| Cat. No.: | HY-P99653 |
| CAS No.: | 1929549-92-7 |
| Target: | Others |
| Pathway: | Others |
| Storage: | Please store the product under the recommended conditions in the Certificate of Analysis. |

BIOLOGICAL ACTIVITY

| | | |
|-------------------------------------|---|---|
| Description | Ianalumab (VAY-736) is a human, decarboxylated antibody against BAFF-R. Ianalumab can block the interaction between BAFF and BAFF-R and antagonize the apoptosis protection mediated by BAFF. Ianalumab exerts antibody-dependent cytotoxic (ADCC), depending on effector cell activation mediated by immune receptor tyrosine activation motif (ITAM) ^[1] . | |
| IC₅₀ & Target | BAFF-R ^[1] | |
| In Vitro | Ianalumab (0.1 µg/mL; 72 h) shows enhanced ADCC and cytokine production induction by chronic lymphocytic leukemia (CLL) NK cells ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. | |
| In Vivo | Ianalumab (Total: 100 mg/kg; once weekly for 2 weeks) increases in vivo survival in CLL mouse models ^[1] . Ianalumab (10 mg/kg; once weekly for 6 weeks) is enhanced by Ibrutinib (HY-10997) through an ITAM function on NK cells ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. | |
| | Animal Model: | Em-TCL1 adoptive transplant model of murine CLL ^[1] |
| | Dosage: | 10 mg/kg |
| | Administration: | Injection; once weekly for 6 weeks |
| | Result: | Ibrutinib enhanced VAY-736 activity through an ITAM function on NK cells. |

REFERENCES

[1]. McWilliams EM, et al. Anti-BAFF-R antibody VAY-736 demonstrates promising preclinical activity in CLL and enhances effectiveness of ibrutinib. Blood Adv. 2019 Feb 12;3(3):447-460.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA